Off-label use is routine in aesthetic medicine. Botox injected into the masseter for slimming, Juvéderm placed in the nose for nonsurgical rhinoplasty, RF microneedling at depths the 510(k) never evaluated — these are off-label applications of FDA-cleared or approved products and devices. The FDA explicitly permits licensed providers to use approved products off-label when supported by sound medical judgment. What the FDA does not do is lower the consent standard. If anything, the obligation to inform the patient increases when the treatment departs from the labeled indication.
This article is for med spa owners, medical directors, and injectors who need to build a consent process that survives both a malpractice claim and a state board audit. It addresses what off-label means, what informed consent requires when the indication is off-label, how to document that conversation without turning the form into a sales document, and where the most common documentation failures occur.
What "Off-Label" Actually Means
When the FDA approves a drug or clears a device, it authorizes specific indications — the clinical uses the manufacturer demonstrated as safe and effective in their submission. In aesthetic medicine, some common examples of FDA-approved indications:
- OnabotulinumtoxinA (Botox Cosmetic): temporary improvement in the appearance of moderate to severe glabellar lines, lateral canthal lines, and forehead lines.
- Hyaluronic acid fillers (Juvéderm, Restylane families): correction of moderate to severe facial wrinkles and folds (e.g., nasolabial folds), lip augmentation, cheek augmentation — each product carries specific approved injection sites.
- CoolSculpting: non-invasive reduction of submental fat, thigh fat, flank fat, abdominal fat, and other localized areas.
When a provider injects Botox into the lateral brow for a "chemical brow lift," uses Restylane Lyft in the temporal fossa, or treats submental fat with deoxycholic acid at a dose above the labeled maximum — that is off-label. The product or device is the same, the regulatory status is the same, but the clinical application falls outside the specific indication the FDA reviewed.
Off-label use is not experimental use. It is not illegal. The American Med Spa Association and the FDA both affirm that licensed providers may use approved products off-label within their scope of practice. The legal obligation shifts to the consent conversation.
The Informed-Consent Standard for Off-Label Use
Informed consent in a medical setting requires the provider to disclose: the nature of the proposed treatment, the expected benefits, the material risks and complications, the alternatives (including no treatment), and the consequences of declining treatment. This is the standard negligence framework that applies in every state.
When the treatment is off-label, two additional disclosures strengthen the consent:
Disclosure that the use is off-label. The patient should understand that the FDA did not evaluate this specific application. From a risk-management perspective, many healthcare attorneys recommend explicit disclosure, even though the legal standard for informed consent — established in cases like Canterbury v. Spence and its state-level progeny — generally asks whether a reasonable patient would want to know, not whether the provider is required to volunteer regulatory status.
Disclosure of the evidence supporting off-label use. If the provider is relying on peer-reviewed literature, professional society guidelines, or extensive clinical experience, that basis should be communicated. An off-label treatment supported by multiple published studies carries a different risk profile from one where the provider is extrapolating from a single case report.
What consent is NOT
Informed consent is not a waiver. A signed form does not protect a provider from a negligence claim if the underlying disclosure was inadequate, the patient did not understand the information, or the provider failed to answer questions honestly. The form documents the conversation — it does not replace it.
Consent is also not marketing. A consent form that lists benefits in promotional language ("achieve a more youthful, refreshed appearance") while burying risks in fine print is a liability document, not a legal shield. Several state medical boards have taken action against practices whose consent forms functioned as sales tools.
Building the Off-Label Consent Document
Structure
An off-label informed-consent form should contain:
Procedure identification. Name the specific product or device, the specific off-label application, and the anatomic site. "Juvéderm Voluma XC injection for tear trough correction" is specific. "Filler treatment" is not.
FDA status disclosure. A clear statement: "This treatment uses [product/device name] for [specific application], which is not an FDA-approved/cleared indication for this product/device. Your provider has determined this use is appropriate for your anatomy and goals based on [clinical experience / peer-reviewed evidence / professional guidelines]."
Risks and complications. List the material risks for the specific off-label application — not just the generic risks from the manufacturer's package insert. Off-label injection sites may carry different vascular anatomy, different depth considerations, and different complication profiles. Tear-trough filler, for example, carries a risk of vascular compromise in the periorbital area that is distinct from nasolabial injection risks. Document the specific risks discussed.
Alternatives. Name at least two alternatives, including the FDA-approved option (if one exists for this site) and the option of no treatment. If the patient is declining an FDA-approved alternative in favor of an off-label approach, document that decision.
Provider qualification statement. State the injector's training and experience with this specific off-label application — number of cases, relevant certifications, or advanced training completed. This is not marketing; it is a factual disclosure supporting the patient's decision to proceed.
Patient acknowledgment. The patient confirms they understand the treatment is off-label, they have had the opportunity to ask questions, and they choose to proceed voluntarily. This should be a separate signature line, not a checkbox buried in a multi-page intake packet.
What to avoid in the form
- Outcome promises. "Expected results" language should be factual and hedged: "May improve the appearance of…" not "Will correct…"
- Minimized risk language. "Rare," "unlikely," and "minimal" are clinical judgments that may be disputed in litigation. Use "possible" and "reported" and list the specific complications.
- Bundled consents. A single consent form covering "all injectable treatments" does not provide procedure-specific informed consent for an off-label application. California's updated med spa regulations specifically require procedure-specific consent for higher-risk treatments including injectables and energy-based devices.
- Pre-signed or electronic auto-consent. Consent must be obtained after the disclosure conversation, before the procedure. Timestamped electronic signatures are defensible; pre-populated forms signed at intake before the provider has evaluated the patient are not.
The Consent Conversation: What the Chart Must Show
The signed form documents that a conversation occurred. The chart note documents what happened in the room. For off-label treatments, the clinical note should include:
- The evaluation. What the provider assessed, what anatomy was examined, what the patient's goals were, and what clinical findings supported the off-label approach over an FDA-approved alternative.
- What was discussed. A note that the provider explained the off-label status, the specific risks of the proposed treatment site and technique, the available alternatives, and the expected course of treatment.
- The patient's questions and responses. If the patient asked about a specific risk or expressed concern, document that the question was answered. This is the strongest defense against a claim that the patient was not adequately informed.
- The decision to proceed. A statement that the patient verbally confirmed understanding and elected to proceed with the off-label treatment after the discussion.
Many medical malpractice carriers require these elements in the chart note — not just the consent form. The American Med Spa Association recommends that supervising physicians review off-label treatment charts as part of their regular chart audit process.
Common Documentation Failures
Generic consent forms. A one-page "injectable consent" that does not mention off-label use, does not name the specific product and injection site, and does not distinguish labeled from off-label indications fails the specificity standard. Regulators in California and New York have specifically flagged generic bundled consents as insufficient for medical spa procedures.
Missing off-label disclosure. The practice uses an off-label technique but the consent form does not mention off-label status. If a complication occurs, the patient's attorney will argue the patient would not have consented had they known the treatment was off-label. Courts generally allow plaintiffs to argue the "reasonable patient" standard: would a reasonable person in this patient's position have wanted this information?
Consent obtained after treatment. The patient signs the consent form in the treatment room after the provider has already begun preparing the injection site. The form's timestamp pre-dates the chart note. This sequence is a common finding in malpractice reviews.
No documentation of the conversation. The consent form is present in the chart, but there is no corresponding clinical note describing the discussion. The provider relies entirely on the form as evidence of informed consent. Board auditors and malpractice reviewers expect both.
Marketing language in the consent form. The form describes the treatment as "a revolutionary, FDA-approved procedure that delivers stunning, natural-looking results." The form calls the product "the gold standard in facial rejuvenation." This language undermines the document's credibility as a risk-disclosure tool and may be treated as evidence that the practice prioritized selling over informing.
State-Specific Considerations
California. Updated med spa regulations effective 2025–2026 require written, procedure-specific informed consent for every medical treatment. Generic or bundled consent forms are explicitly insufficient for injectables, lasers, and energy-based devices. Consent must clearly outline the treatment description, expected outcome, risks, complications, alternatives, and precare and postcare instructions. The consent must be obtained before treatment and documented in the patient's chart.
New York. Physician misconduct rules require medical records to accurately reflect evaluation and treatment. New York's informed-consent standard follows the "reasonable patient" test — what a reasonable patient would want to know. Documentation should show what the patient was seeking, what the provider evaluated, what treatment was selected, and what risks, benefits, and alternatives were discussed.
Texas. The Texas Medical Board's supervision and delegation rules require that delegation agreements specify the scope of delegated acts and that the delegating physician maintain appropriate supervision. When delegated acts involve off-label use, the supervising physician's chart review should verify that the off-label consent was obtained and documented.
Florida. Florida's informed-consent law (Fla. Stat. §766.103) creates a presumption against liability when the provider can demonstrate compliance with the informed-consent statute — but only if the consent was obtained in a manner that meets the statutory requirements, including disclosure of the "material risks" of the proposed procedure.
Practical Implementation
Step 1: Audit your consent library
Review every consent form in use. For each form, confirm it names the specific product or device, the specific anatomic site, and whether the application is FDA-approved or off-label. If a form covers multiple procedures in one document, separate them.
Step 2: Create off-label addenda
For your most common off-label applications — masseter Botox, nonsurgical rhinoplasty with filler, temporal filler, RF microneedling for acne scarring — create procedure-specific consent addenda that disclose off-label status, list the relevant risks for that site, and name alternatives.
Step 3: Train the team
Ensure every provider who performs off-label treatments can articulate the off-label status, the evidence basis, and the specific risks in plain language. Consent conversations should not be delegated to front-desk staff. The provider performing the procedure should conduct the consent discussion.
Step 4: Document the conversation in the chart
Add a structured consent note template to your charting workflow that captures: off-label status disclosed, specific risks discussed, alternatives presented, patient questions answered, patient elected to proceed. This takes 60 seconds to complete and is the single highest-yield risk-management step in the process.
Step 5: Include off-label consent in chart audits
The medical director's periodic chart review should verify that off-label treatments have both a procedure-specific consent form and a corresponding chart note documenting the discussion. Flag charts where off-label treatment was performed without explicit off-label disclosure.
Sources
- U.S. Food and Drug Administration. "Understanding Unapproved Use of Approved Drugs 'Off-Label.'" https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label
- American Med Spa Association. "Patient Guide." https://www.americanmedspa.org/patient-guide
- Much Shelist, P.C. "Why Informed Consent Is Essential for Med Spas." https://www.muchlaw.com/insights/why-informed-consent-is-essential-for-med-spas
- Phorest. "Compliance Checklist for California Med Spas: 2026 Edition." https://www.phorest.com/us/blog/compliance-checklist-for-california-med-spas-2026-edition
- Phorest. "Compliance Checklist for Med Spas in New York: 2026 Edition." https://www.phorest.com/us/blog/compliance-checklist-for-med-spas-in-new-york-2026-edition
- Business of Aesthetics. "How to Protect Your Aesthetic Practice and Avoid Costly Legal Mistakes." https://www.businessofaesthetics.org/blog/aesthetic-practice-legal-compliance-guide
- Aesthetic Compliance Experts. "Med Spa Compliance Guide 2025: Key Regulations & Best Practices." https://www.aestheticcomplianceexperts.com/post/medspa-compliance-master-the-requirements-for-2025
